Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Combination regimens of 3 active drugs have shown promising activity in treatment of
metastatic gastric cancer. Docetaxel combined with cisplatin and 5-fluorouracil (FU) yielded
superior overall survival and response rates when compared to standard cisplatin and 5-FU.
However, a toxicity profile showed the need for development of less toxic modifications. In a
prior phase I trial, the maximum tolerated dose was defined. In this phase II trial, a first
evaluation of activity will be performed.